Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mercury Biopharmaceutical has a quick ratio of 8.84. It generally indicates good short-term financial strength.
The historical rank and industry rank for Mercury Biopharmaceutical's Quick Ratio or its related term are showing as below:
ROCO:6932'
s Quick Ratio Range Over the Past 10 Years
Min: 0.32 Med: 8.84 Max: 42.21
Current: 8.84
During the past 7 years, Mercury Biopharmaceutical's highest Quick Ratio was 42.21. The lowest was 0.32. And the median was 8.84.
ROCO:6932's Quick Ratio is ranked better than 94.19% of 999
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs ROCO:6932: 8.84
Mercury Biopharmaceutical (ROCO:6932) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Mercury Biopharmaceutical Quick Ratio Related Terms
Mercury Biopharmaceutical Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Biopharmaceutical's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mercury Biopharmaceutical Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mercury Biopharmaceutical's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Mercury Biopharmaceutical's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Mercury Biopharmaceutical's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mercury Biopharmaceutical (ROCO:6932) has a Quick Ratio of 8.84 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Mercury Biopharmaceutical and its competitors. This is near median its historical median of 8.84. Over the past decade, Mercury Biopharmaceutical's Quick Ratio has ranged from 0.32 to 42.21. According to the industry distribution chart, Mercury Biopharmaceutical ranks #58 out of 999 companies in the Drug Manufacturers industry, placing it in the top 5.8%.
Is Mercury Biopharmaceutical's Quick Ratio too high?
Mercury Biopharmaceutical's current Quick Ratio of 8.84 is near median its 10-year median of 8.84. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 42.21. The Drug Manufacturers industry median Quick Ratio is 1.45. Mercury Biopharmaceutical's value of 8.84 is 509.7% above this industry median. Based on the distribution chart, Mercury Biopharmaceutical ranks #58 out of 999 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Mercury Biopharmaceutical has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mercury Biopharmaceutical's Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mercury Biopharmaceutical ranks #58 out of 999 companies for Quick Ratio. This places Mercury Biopharmaceutical in the top 6% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. Mercury Biopharmaceutical's value of 8.84 is 509.7% above this benchmark. Historically, Mercury Biopharmaceutical's own Quick Ratio has ranged from 0.32 to 42.21 over the past decade. While the company's 10-year median is 8.84 vs. the industry median of 1.45, Mercury Biopharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mercury Biopharmaceutical's current Quick Ratio of 8.84 is 509.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Mercury Biopharmaceutical and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mercury Biopharmaceutical's current Quick Ratio is 8.84, which is near median its own 10-year median of 8.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercury Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Mercury Biopharmaceutical (ROCO:6932) is currently considered Possible Value Trap. The stock's GF Value™ is NT$36.00, compared to a current price of NT$5.93 — trading 83.5% below its estimated fair value. The current Quick Ratio is 8.84, which is near median its 10-year median of 8.84 and 509.7% above the Drug Manufacturers industry median of 1.45. Mercury Biopharmaceutical's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Mercury Biopharmaceutical (ROCO:6932), the current Quick Ratio is 8.84 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mercury Biopharmaceutical (ROCO:6932) Overvalued in 2026?
Based on GuruFocus' analysis, Mercury Biopharmaceutical stock appears to be undervalued.
The current stock price of NT$5.93 is trading 83.5% below its estimated GF Value™ of NT$36.00.
GuruFocus considers Mercury Biopharmaceutical to be Possible Value Trap.
Key valuation signals for ROCO:6932:
Quick Ratio: 8.84 (near median its 10-year median of 8.84)
GF Value™: NT$36.00 vs. price of NT$5.93 (83.5% below fair value)
Industry Position: 509.7% above the Drug Manufacturers median (#58 of 999)
No single metric tells the full story. See the ROCO:6932 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.
25GF Score
Get the complete analysis for ROCO:6932
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6932 has been successfully added to your 
